When it comes to the S&P 500 and one of the ETFs that represents the overall biotech sector (the iShares Nasdaq Biotechnology ETF), the author of today’s article observes that “the paths of these two investments appear to be diverging.” Given this apparent divergence, he questions whether, despite all the recent medical news, biotech stocks have already had their run.…
“2020 will be remembered as the year of the biotech sector,” declares the author of today’s article, who proceeds to highlight two biotech stocks that Morgan Stanley is bullish on – and which have also earned “Strong Buy” consensus ratings from the analyst community at large. For these two biotech stocks with significant upside potential, CLICK HERE.
When it comes to the uncertainty that currently permeates the market as a result of the pandemic and impending election, the chief investment strategist at Oppenheimer is choosing to embrace it. As a result, today’s article takes a look at two specific stocks Oppenheimer is bullish on – and which its analysts believe have over 100% upside potential (792% in…
“Many investors, especially more aggressive traders, look at lower-priced stocks as a way to not only make some good money but to get a higher share count,” notes the author of today’s article. He proceeds to highlight five low-priced biotech and medtech stocks with significant upside potential to consider for very aggressive accounts. For these five stocks – including a…
In January, the small-cap biotech highlighted in today’s article received FDA approval for its treatment for childhood peanut allergy – and with peanut allergy being the most common food allergy in the U.S. (with cases of the condition rising rapidly) and the fact that this is currently the only FDA-approved treatment for the condition (thanks to a competitor encountering some…
Joining the ever-expanding list of COVID-19 stocks is this biotech that has filed an application with the FDA for initiation of Phase 2/Phase 3 clinical trials for its experimental monoclonal antibody therapy for the disease. The safety and tolerability of the therapy has already been demonstrated and, as today’s article explains, the company believes that its modulating effect “could reduce…
Of all the companies working on the development of potential COVID-19 vaccines and therapeutics, the one highlighted in today’s article – a small Israel-based biotech that specializes in blood plasma-based treatments – is one of the least well-known. However, given that plasma-based therapies have already been shown to be effective in treating severe cases of COVID-19, this company could start…
Noting that “biotechnology and healthcare penny stocks are making waves in the market”, the author of today’s article highlights four biotech penny stocks to watch that have been gaining attention this year, both for developments related to the COVID-19 crisis and developments unrelated to the COVID-19 crisis. For these four biotech penny stocks to watch, CLICK HERE.
“While large-cap stocks might spike slightly on certain headlines, more times than not, penny stocks tend to experience a compound effect,” notes the author of today’s article, who proceeds to examine three penny stocks that have recently had big news – and what that news could mean for those stocks heading into the final week of July. For more, CLICK…
Are we approaching the end of the TINA – “There Is No Alternative” (to buying stocks) – trade? The author of today’s article believes that’s likely the case, stating that “U.S. stocks are trading at a historically high premium… And in the coming weeks, stocks are about to get a lot more expensive. This, coupled with the realities associated with…